JP2006043360A - Method for grasping whole picture in quality and quantity of fat - Google Patents

Method for grasping whole picture in quality and quantity of fat Download PDF

Info

Publication number
JP2006043360A
JP2006043360A JP2004247545A JP2004247545A JP2006043360A JP 2006043360 A JP2006043360 A JP 2006043360A JP 2004247545 A JP2004247545 A JP 2004247545A JP 2004247545 A JP2004247545 A JP 2004247545A JP 2006043360 A JP2006043360 A JP 2006043360A
Authority
JP
Japan
Prior art keywords
lipid
quality
radar chart
ldl
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004247545A
Other languages
Japanese (ja)
Inventor
Takehide Matsuda
武英 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASUKA TOKUSHU KENSA KENKYUSHO
ASUKA TOKUSHU KENSA KENKYUSHO KK
Original Assignee
ASUKA TOKUSHU KENSA KENKYUSHO
ASUKA TOKUSHU KENSA KENKYUSHO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASUKA TOKUSHU KENSA KENKYUSHO, ASUKA TOKUSHU KENSA KENKYUSHO KK filed Critical ASUKA TOKUSHU KENSA KENKYUSHO
Priority to JP2004247545A priority Critical patent/JP2006043360A/en
Publication of JP2006043360A publication Critical patent/JP2006043360A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To support health management by providing the whole situation of fat in a form to allow not an expert but a patient or a physical examination receiver to understand it. <P>SOLUTION: The inspection result of the quality and quantity of the fat is expressed at a time by a radar chart. Accordingly, the whole situation of the fat is made to be understood so as to synthetically grasp the risk of arteriosclerosis or myocardial infarction at a glance. A plurality of cases are determined, where the fat is highly risky in quality but normal in quantity or, on the contrary, the fat is a little risky in quantity but not abnormal in quality, etc. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

病院や健診センターおよび登録衛生検査所における臨床検査結果報告書などの表記方法に関する分野。Fields related to notation methods such as reports on clinical test results at hospitals, health check centers, and registered hygiene laboratories.

従来よりレーダーチャートは、情報を解かり易く表現する方法として折線グラフや円グラフ、棒グラフなどと同じく広く一般に使われている。
医療分野についても、いろいろな臨床所見や検査結果の統計的表現として、学会発表や報告書などで日常的に使われている。しかしこれらの報告書は医師である専門家向けに報告するものとされ、検査結果の羅列で概ね事足りていた。また個人向けの健診結果報告書の場合についても、多数の測定項目の検査結果がただ数値として羅列されている場合が殆どであった。
Conventionally, radar charts have been widely used as a method of expressing information in an easy-to-understand manner, like line graphs, pie charts, and bar graphs.
Also in the medical field, it is used daily in conference presentations and reports as a statistical expression of various clinical findings and test results. However, these reports were supposed to be reported to specialists who are doctors, and the list of test results was generally sufficient. Also, in the case of personal checkup results reports for individuals, most of the test results of many measurement items are listed as numerical values.

最近、生活習慣病として高血圧、糖尿病、高脂血症が定着してきている。
高血圧、糖尿病については個人で血圧計や尿糖あるいは血糖検査を自己検査する事が出来るようになってきている。しかし高脂血症については、血液検査で病院の診療や健診検査を受けない限り、高脂血症かどうかは分からない。
Recently, hypertension, diabetes, and hyperlipidemia have become established as lifestyle-related diseases.
With regard to high blood pressure and diabetes, it has become possible for individuals to self-examine blood pressure monitors, urine sugar or blood glucose tests. However, as for hyperlipidemia, it is not known whether it is hyperlipidemia unless a blood test is performed at a hospital or a medical examination.

高脂血症については、健診結果や一般に市販されている医学関係の解説書籍などを見る限り、全て脂質の量を中心に書かれている。非特許文献1の日経メデイカル誌1997年6月号の特集記事には、高脂血症の治療の目的は動脈硬化を予防し心筋梗塞を起さないためになされるものであり、そのためには脂質の量ばかりではなく脂質の質の検査も大切であると記載されている。Hyperlipidemia is written mainly on the amount of lipid as far as medical examination results and medical commentary books that are generally available on the market are examined. In the special article of the non-patent document 1 June 1997 issue of Nikkei Medical, the purpose of hyperlipidemia treatment is to prevent arteriosclerosis and prevent myocardial infarction. It is described that not only the amount of lipid but also examination of lipid quality is important.

高脂血症においては、ごく一部の専門の医師の間でのみ脂質の量と質の両面を見て診療に役立てている。この脂質の質を見る検査法は手間と時間がかかることおよびその判定がごく少数の専門医でないと出来ないという問題点があり、特に健診領域にこれらは普及していなかった。In hyperlipidemia, only a small number of specialized doctors use both the amount and quality of lipids for medical care. This method of examining the quality of lipids is troublesome and time consuming, and has the problem that it can only be judged by a few specialists, and these have not been particularly popular in the medical examination area.

また血清の濁り度は、一般的に乳ビ血清または乳ビ血漿とよばれ、病院等の臨床検査室では濁り度+1や+2と目視で表現する方法が採られていた。The turbidity of serum is generally called milk serum or milk plasma, and a method of visually expressing turbidity +1 or +2 has been adopted in clinical laboratories such as hospitals.

参考文献
非特許文献1 高脂血症治療の曲がり角、日経メデイカル誌 1997年6月号、60−69
非特許文献2 田代淳他:家族性高コレステロール血症における Midbandの意義、動脈硬化、Vol.15,No.8,1561−1564,1988
非特許文献3 三島康男他:ベザフィブレート徐放錠投与の血清脂質、リポ蛋白電気泳動に及ぼす影響、Therapeutic Research,vol,14,no.10,4489−4497,1993
非特許文献4 三島康男他:簡便なPAG電気泳動キットを用いたLDL粒子サイズの推定、動脈硬化,vol.25,no.1・2,67−70,1997
非特許文献5 平野 勉:新しいSmall,dense LDL定量法、日本臨床検査自動化学会誌、第29巻第2号、81−87、2004年7月26日
特許文献1 特願2003−387226
Reference Non-Patent Document 1 Curvature of Hyperlipidemia Treatment, Nikkei Medical, June 1997, 60-69
Non-Patent Literature 2 Tashiro Satoshi et al .: Significance of Midband in Familial Hypercholesterolemia, Arteriosclerosis, Vol. 15, no. 8,1561-1564, 1988
Non-patent document 3 Yasuo Mishima et al .: Effects of administration of bezafibrate sustained-release tablets on serum lipids and lipoprotein electrophoresis, Therapeutic Research, vol, 14, no. 10, 4489-4497, 1993
Non-Patent Document 4 Yasuo Mishima et al .: Estimation of LDL particle size using a simple PAG electrophoresis kit, arteriosclerosis, vol. 25, no. 1, 2, 67-70, 1997
Non-Patent Document 5 Tsutomu Hirano: New Small, dense LDL quantification method, Journal of Japanese Society for Clinical Laboratory Automation, Vol. 29, No. 2, 81-87, July 26, 2004 Patent Document 1 Japanese Patent Application No. 2003-387226

課題を解決するための手段Means for solving the problem

本願発明は、脂質の質と量を1つのレーダーチャートで一緒に表現し個人の脂質の全体像を把握し易くするための方法を提供するものである。脂質の質の検査としては非特許文献1、2、3にあるようなポリアクリルアミドゲルデイスク電気泳動像の分析結果を利用して、リポ蛋白粒子であるVLDL,LDL,HDLやミッドバンドと呼ばれるIDLや小粒子LDLと呼ばれるSmall LDL等を使用する。また脂質の量の検査としては一般的な検査として日常的に使われている総コレステロール、LDLコレステロール、HDLコレステロール、中性脂肪等を利用する。また糖尿病は脂質代謝と関連が強く血糖値やヘモグロビンA1Cなども関連検査として利用することも可能である。この脂質や糖質の量の測定法については病院検査関係者や専門者間では余りにもよく知られているのでここでは省略する。The present invention provides a method for making it easy to grasp the overall image of an individual lipid by expressing the quality and quantity of the lipid together on one radar chart. For the examination of lipid quality, analysis results of polyacrylamide gel disk electrophoresis images as described in Non-Patent Documents 1, 2, and 3 are used, and IDL called VLDL, LDL, HDL, which is a lipoprotein particle, or midband. Or Small LDL called small particle LDL. As the lipid amount test, total cholesterol, LDL cholesterol, HDL cholesterol, neutral fat and the like which are routinely used as a general test are used. Diabetes is strongly related to lipid metabolism, and blood glucose levels and hemoglobin A1C can also be used as related tests. This method for measuring the amount of lipids and sugars is omitted here because it is well known among hospital inspection personnel and experts.

肥満度については、肥満を診察している医師の間では最も一般的な指標であるBMI(標準体重、ボデイマス・インデックス、日本肥満学会)を使用する。BMIは、体重/(身長×身長)で表され18.5〜25未満が正常で、25以上は肥満ということになる。逆に18.5未満がやせぎみと言われている。Regarding the degree of obesity, BMI (standard body weight, body mass index, Japanese Society of Obesity), which is the most common index among doctors examining obesity, is used. BMI is expressed as body weight / (height × height), and normal is less than 18.5 to 25, and 25 or more is obese. Conversely, less than 18.5 is said to be thin.

血清の濁り度を表現する方法については、一般的には検査技師の目視により+1や+2と表現されている。これは個人的感覚的な部分が多すぎるので、本願発明ではJIS K−0400−9−10で濁度の指標とされているホルマジン濁度を使用するが、目視判定結果でも同じようなチャートが書ける。The method of expressing the turbidity of serum is generally expressed as +1 or +2 by visual inspection by a laboratory technician. Since there are too many personal sensory parts, the present invention uses formazine turbidity, which is an index of turbidity in JIS K-0400-9-10. I can write.

これらの従来の脂質の質と量の検査は今まではそれぞれ単独で使われていたが、本願発明ではこれらを関連させたレーダーチャートを用いることで、専門家はもとより、動脈硬化や高脂血症に興味のある一般の人でも簡単に自身の脂質の質と量の状態を知ることができるようになった。Until now, these conventional lipid quality and quantity tests have been used independently, but in the present invention, by using a radar chart associated with them, not only specialists but also arteriosclerosis and hyperlipidemia. Even ordinary people interested in the disease can easily know the status of their lipid quality and quantity.

レーダーチャートは多変量のデータ解析法であり、結果の解釈に直結するグラフとして統計学では広く一般に使われている。
このレーダーチャートを、脂質の質と量の解析に使用することは、今まで曖味であった脂質の全体像の把握に大きなインパクトを与える。
Radar chart is a multivariate data analysis method, and is widely used in statistics as a graph directly connected to interpretation of results.
Using this radar chart to analyze the quality and quantity of lipids has a great impact on understanding the overall picture of lipids, which has been vague until now.

本願発明は脂質の質の検査結果と量の検査結果の他、肥満度や血液の濁り度である乳ビ値をそれぞれ変数として選びレーダーチャートを構成させた。
脂質の質の検査としては、ポリアクリルアミドゲルデイスク電気泳動法の結果からリポ蛋白質のミッドバンド(IDLとも言う)および小粒子LDL(Small LDLとも言う)の情報を変数軸として選ぶ。質の検査法として最近発表された非特許文献5によるリポ蛋白沈殿法を変数として取り入れても差し支えない。また、VLDL,LDL,HDLそれぞれもその存在比率は、脂質の正常者と異なる脂質異常者がいるのでそれも変数軸に取り上げることも可能である。
In the present invention, in addition to the lipid quality test results and quantity test results, milky values, which are obesity levels and turbidity levels of blood, are selected as variables, and a radar chart is constructed.
As a lipid quality test, information on the lipoprotein midband (also referred to as IDL) and small particle LDL (also referred to as Small LDL) is selected as a variable axis from the results of polyacrylamide gel disk electrophoresis. The lipoprotein precipitation method according to Non-Patent Document 5 recently published as a quality inspection method may be incorporated as a variable. In addition, since there are lipid abnormalities in VLDL, LDL, and HDL, the existence ratios of which are different from normal lipids, it is possible to take them on the variable axis.

脂質の量の検査としては、一般的に使われている総コレステロール値、LDLコレステロール値、HDLコレステロール値、中性脂肪値を変数に選ぶ。脂質の量の検査法として何種類かのアポ蛋白質を変数の一つとして取り上げても何ら差し支えない。また脂質代謝に関係があるLDLリパーゼなどの酵素の定量値、さらに関連検査として血糖値、ヘモグロビンA1C等の糖質の検査も追加してもよい。For testing the amount of lipid, commonly used total cholesterol level, LDL cholesterol level, HDL cholesterol level, and neutral fat level are selected as variables. It is safe to take several types of apoproteins as one of the variables as a method for testing the amount of lipid. Further, a quantitative value of an enzyme such as LDL lipase related to lipid metabolism, and a blood sugar level and a carbohydrate test such as hemoglobin A1C may be added as a related test.

各変数の基準の取り方として、まず脂質の量の診断基準として動脈硬化学会で示された値を健常値の上限とする。たとえば上限をそれぞれ総コレステロール値は220mg/dL、LDLコレステロール値は140mg/dLとし、中性脂肪値は150mg/dLとする。またHDLコレステロール値の下限は40mg/dLとする。
肥満度も一般的に専門医の間で推奨されている25を健常の上限とし18.5未満がやせぎみとする。この数字そのものは時代の趨勢で変わることもある。
乳ビ量については、今まで目視で判定していたものをJISで濁度の基準とされたホルマジン濃度を使う。従来の検査技師の主観による目視判定の+1、+2、+3という値を使用しても差し支えない。脂質の臨床検査としては、普通採血は12時間程度の絶食後の採血が望ましいとされ、脂質正常者の血清もしくは血漿は透明であり濁り度はないと言われている。従ってレーダーチャートでは正常基準輪以下にデータは存在しない。
As a method of taking the criteria for each variable, first, the value shown by the Arteriosclerosis Society as a diagnostic criterion for the amount of lipid is used as the upper limit of the healthy value. For example, the total cholesterol value is 220 mg / dL, the LDL cholesterol value is 140 mg / dL, and the neutral fat value is 150 mg / dL. The lower limit of the HDL cholesterol value is 40 mg / dL.
The degree of obesity is generally 25, which is generally recommended among specialists, and the upper limit of health is less than 18.5. This number itself may change with the trend of the times.
For the amount of milk powder, the formazine concentration that has been determined visually until now is used as the turbidity standard in JIS. The values +1, +2, and +3 of the visual judgment based on the subjectivity of the conventional inspection engineer may be used. As clinical tests for lipids, it is said that blood collection after fasting for about 12 hours is desirable for normal blood collection, and serum or plasma of normal lipid subjects is said to be transparent and free from turbidity. Therefore, there is no data below the normal reference wheel in the radar chart.

脂質の質の判定方法について、通常脂質の正常者には脂質の質の異常は原則無いのが普通であり、質的異常の出現はすなわち正常でないと言うことになる。この異常出現の判定については、非特許文献4に詳しく記載されている。いわゆるミッドバンド(IDLとも言う、大粒子LDLを指すこともある)の中央値のMIインデックスが0.2のグループを指し、小粒子の中央値のMIインデックスが0.41のグループを指しそれぞれの存在%値を変数軸にプロットしてレーダーチャートを構成させる。
小粒子LDLの中央値のMIインデックスが0.35以上では小粒子の可能性があると指摘されていることから、ここに記載した0.2もしくは0.41値は必ずしも固定されたものではない。
Regarding the method for determining lipid quality, it is normal that a normal lipid person usually has no abnormality in lipid quality, and the appearance of a qualitative abnormality is not normal. This determination of abnormal appearance is described in detail in Non-Patent Document 4. The median MI index of the so-called mid-band (also referred to as IDL, sometimes referred to as large particle LDL) indicates a group of 0.2, and the median MI index of small particles indicates a group of 0.41. A radar chart is constructed by plotting the existence% value on the variable axis.
Since it has been pointed out that there is a possibility of small particles when the median MI index of small particles LDL is 0.35 or more, the 0.2 or 0.41 values described here are not necessarily fixed. .

MIインデックスの名称については、報告した医師により若干意味合いは違う。電気泳動的に荷電量もしくはサイズを現すものとして専門家の間で古くから使われていたRm値とかRf値を使用しても差し支えない。The name of the MI index is slightly different depending on the doctor who reported it. An Rm value or Rf value that has been used by experts for a long time as an electrophoretic charge amount or size may be used.

レーダーチャートの正常基準輪に対し、個人の測定値の採りかた方は2通りあり、ここでは基準輪より凸の部分が異常とする方式を採用した。基準輪より内側に凹の部分を異常とするレーダーチャートも想定できる。There are two ways of taking individual measurement values with respect to the normal reference wheel of the radar chart. Here, a method is adopted in which the convex part of the reference wheel is abnormal. A radar chart in which a concave portion is abnormal inside the reference wheel can be assumed.

脂質代謝は血糖の代謝も深い関係にあり、高脂血症においては糖尿病の患者が多数存在する。糖尿病患者の脂質の全体像を掴むには、血糖とヘモグロビンA1Cおよび1・5AGまたはフルクトサミンの定量値をレーダーチャートに加え糖尿病管理に使用することも可能である。Lipid metabolism is also closely related to blood glucose metabolism, and there are many patients with diabetes in hyperlipidemia. In order to get an overall picture of lipids of diabetic patients, it is also possible to add blood glucose and hemoglobin A1C and quantitative values of 1.5 AG or fructosamine to the radar chart and use them for diabetes management.

脂質の質と量のレーダーチャートの見方としてたとえば図1の場合、(1)〜(5)の脂質の量において正常基準輪(9)を一部越えていても、脂質の質である(6)〜(8)が正常である場合は、心筋梗塞のリスクは低いと判断でき、また逆に(1)〜(5)の脂質の量において正常基準輪(9)以内であったとしても、脂質の質である(6)〜(8)が異常である場合は、心筋梗塞のリスクを否定できないことになる。In the radar chart of lipid quality and quantity, for example, in the case of FIG. 1, even if the quantity of lipid of (1) to (5) partially exceeds the normal reference wheel (9), the quality of lipid (6 ) To (8) are normal, it can be judged that the risk of myocardial infarction is low, and conversely, even if the amount of lipid in (1) to (5) is within the normal reference ring (9), When the lipid quality (6) to (8) is abnormal, the risk of myocardial infarction cannot be denied.

図1に8個の変数軸を持ったレーダーチャートを示す。上段に肥満度(1)をとり右回りに総コレステロール(2)を次にLDLコレステロール(3)、(4)にHDLコレステロールを、(5)に中性脂肪、(6)に乳ビ量を(7)に小粒子LDL、(8)にミッドバンド(IDLとも言う)を選んだ。中央の波線の輪(9)は正常者の脂質の全体像いわゆる正常基準輪である。
(2)から(6)までが脂質の量を現し、(7)と(8)が脂質の質を現している。(6)の乳ビ量、(7)の小粒子LDL、(8)のミッドバンド(IDLとも言う)は、正常者では出現しない部分でそれを斜線(10)で示した。(11)の太い実践は、健診患者Aの脂質レーダーチャートの例で、この患者は総コレステロール(1)とLDLコレステロール(2)は若干高いが、脂質の質である小粒子LDL(7)とミッドバンド(8)は正常であり心筋梗塞等のリスクは少ないことを示している。
FIG. 1 shows a radar chart having eight variable axes. Upper level is obesity level (1), clockwise total cholesterol (2), then LDL cholesterol (3), (4) HDL cholesterol, (5) neutral fat, (6) milk content Small particles LDL were selected for (7) and midband (also referred to as IDL) for (8). The wavy ring (9) in the center is a so-called normal reference ring, which is an overview of lipids of normal subjects.
(2) to (6) represent the amount of lipid, and (7) and (8) represent the quality of the lipid. The milk amount of (6), the small particle LDL of (7), and the midband (also referred to as IDL) of (8) are the portions that do not appear in normal subjects and are indicated by hatching (10). The fatal practice of (11) is an example of a lipid radar chart of a health checkup patient A, who has a slightly higher total cholesterol (1) and LDL cholesterol (2), but a small particle LDL (7) that is of lipid quality. And the mid band (8) is normal, indicating that the risk of myocardial infarction is low.

図2に6個の変数軸を持ったレーダーチャートを示す。上段に総コレステロール(12)を次にLDLコレステロール(13)、(14)にHDLコレステロールを、(15)に中性脂肪、(16)に小粒子LDL、(17)にミッドバンドを選んだ。(18)は正常基準輪である。。(12)から(15)までが脂質の量を現し、(16)と(17)が脂質の質を現している。
(19)が健診患者Bのレーダーチャートによる分析結果であり、脂質の量は正常だが(17)のミッドバンド(IDLともいう)が少し出ており動脈硬化のリスクがあることを示している。
FIG. 2 shows a radar chart having six variable axes. Total cholesterol (12) was selected at the top, LDL cholesterol (13), (14) HDL cholesterol, (15) neutral fat, (16) small LDL, and (17) midband. (18) is a normal reference wheel. . (12) to (15) represent the amount of lipid, and (16) and (17) represent the quality of the lipid.
(19) is the analysis result of the medical examination patient B by the radar chart, and the amount of lipid is normal, but the mid band (also referred to as IDL) of (17) is a little, indicating that there is a risk of arteriosclerosis. .

図3に8個の変数軸を持ったレーダーチャートを示す。上段に総コレステロール(20)を次にLDLコレステロール(21)、(22)にHDLコレステロールを、(23)に中性脂肪、(24)に血糖値、(25)にヘモグロビンA1Cを、(26)に小粒子LDL、(27)にミッドバンドを選んだ。
(28)は脂質と糖質の正常基準輪である。(20)から(25)までが脂質および糖質の量を現し、(26)と(27)が脂質の質を現している。
(29)が健診患者Cのレーダーチャートによる分析結果であり、脂質と量および糖尿病指標は正常者を上回っておりリスクが高いことが明白である。
FIG. 3 shows a radar chart having eight variable axes. Total cholesterol (20) at the top, then LDL cholesterol (21), (22) HDL cholesterol, (23) neutral fat, (24) blood glucose, (25) hemoglobin A1C, (26) Small particle LDL was selected for (2) and midband was selected for (27).
(28) is a normal reference ring for lipids and carbohydrates. (20) to (25) represent the amount of lipid and carbohydrate, and (26) and (27) represent the lipid quality.
(29) is the analysis result of the medical examination patient C by the radar chart, and it is clear that the lipid, the amount, and the diabetes index are higher than those of normal persons and the risk is high.

図4に脂質の質について6個の変数軸を持ったレーダーチャートを示す。上段にVLDL(30)を右回りにミッドバンドまたはIDL(31)、LDL(32)、小粒子LDLまたはSmall LDL(33)、HDL(34)、乳ビ(35)をとった。IDL(31)とSmall LDL(33)および乳ビ(35)は正常者には検査結果が存在しないので(36)の正常基準輪の内側は斜線(37)で塗りつぶした。
(38)が健診患者Dのレーダーチャートによる分析結果であり、脂質の質全般にわたって異常を示している。しかし血液の濁りの指標である乳ビ(35)が無い症例である。
FIG. 4 shows a radar chart with six variable axes for lipid quality. In the upper part, VLDL (30) was taken clockwise, and midband or IDL (31), LDL (32), small particle LDL or Small LDL (33), HDL (34), and milk (35) were taken. Since IDL (31), Small LDL (33), and milk (35) have no test results in normal subjects, the inside of the normal reference ring of (36) is filled with diagonal lines (37).
(38) is the analysis result by the radar chart of the medical examination patient D, and shows abnormality over the whole quality of lipid. However, this is a case without milky milk (35), which is an indicator of blood turbidity.

発明の効果The invention's effect

本願発明は非特許文献1に「高脂血症を治療する最大の目的は冠疾患の予防にある。ところが最近、循環器の専門家からの間から、高脂血症患者を治療しても期待したほどの成果があがっていないのではないか。」と特集記事が掲載されてから久しい。専門家さえこのような疑問の声がある現在、一般的な脂質量の測定結果を中心とする検診だけで「心筋梗塞の心配ないです」と果たして言えるかという疑問がある。The invention of the present application states in Non-Patent Document 1 that “the greatest purpose of treating hyperlipidemia is prevention of coronary disease. It's been a long time since the feature article was published, "Isn't the result as expected?" Even now, even experts have such a question, there is a question whether it can be said that there is no worry about myocardial infarction only by screening mainly on the measurement result of general lipid content.

脂は水に溶けないことは明白で、血液中では必ず粒子状のリポ蛋白質構成成分の1部として存在している。このリポ蛋白質の存在形態すなわち粒子状態を調べるのがいわゆる脂質の質の検査と言うことになる。このリポ蛋白粒子が代謝不良や過剰状態により質的異常を起こし結局、動脈硬化や高脂血症を発症すると言われている。勿論脂質の質だけでなく量的異常は一般的に悪玉・善玉コレステロールとしてよく知られているように、重要な指標であることには異存を挟む余地はない。It is clear that fat does not dissolve in water, and it is always present as a part of particulate lipoprotein constituents in blood. Examining the existence form of the lipoprotein, that is, the particle state, is a so-called lipid quality test. It is said that these lipoprotein particles cause qualitative abnormalities due to poor metabolism or excessive state, and eventually cause arteriosclerosis and hyperlipidemia. Of course, not only the quality of lipid but also quantitative abnormalities are well known as bad and good cholesterol, and there is no room for objection to being an important indicator.

この重要な脂質の質と量は、同時に見ることこそ価値があり、現在一部の専門家はこの事実を診療に役立てている。何故一部の専門家しか診療に役立っていないかというと、脂質の質の検査はまだ余り普及していないためである。
最近自己の健康は自分で守る自己責任の時代を迎え、たとえ検診の結果であっても、個人の健康状態について真実の姿を知っておくことは、動脈硬化の予防に必ずつながる。今後は患者がもっと積極的に自分の健康維持に注意を払うべきその道具の1つを本願発明は提供することとなる。
This important lipid quality and quantity is worth seeing at the same time, and some experts are now using this fact in their practice. The reason why only some specialists are useful in medical care is because lipid quality tests are not yet widely used.
Recently, the self-responsibility era of self-responsibility has come, and knowing the truth about the individual's health status, even as a result of screening, will surely prevent arteriosclerosis. In the future, the present invention will provide one of the tools that patients should pay more attention to maintaining their health.

脂質の質と量の検査結果を、対比させて表記したものは今までになく、例え量的に異常であっても質的に異常が無かったり、量的には健常であっても質的に異常がある場合もある。本願発明の「脂質の質と量の全体像を把握する方法」が普及する事で、高脂血症がより理解されかつ健康に対する認識が高まる。
言い換えるならば、本願発明の普及により、現在行われている脂質の量的異常だけを見て悪玉とか善玉という不完全な常識を打破出来ることになり、患者や一般の人もこれらの真実を認識を新たにし、結果的に適切な高脂血症治療を受けることができ、医療費の増大を防止し、健康の維持に貢献することが出来る。
There has never been a comparison of lipid quality and quantity test results, and there is no qualitative abnormality even if it is abnormal in quantity, or it is qualitative even if it is healthy in quantity. There may be abnormalities. With the widespread use of the “method for grasping the overall picture of the quality and quantity of lipid” of the present invention, hyperlipidemia is better understood and health awareness is increased.
In other words, with the spread of the present invention, it will be possible to break down the incomplete common sense of bad or good by looking at only the quantitative abnormality of lipids currently being carried out, and patients and ordinary people also recognize these truths As a result, it is possible to receive appropriate hyperlipidemia treatment, prevent an increase in medical expenses, and contribute to maintaining health.

8個の変数軸を持った脂質のレーダーチャート  Lipid radar chart with 8 variable axes 6個の変数軸を持った脂質のレーダーチャート  Lipid radar chart with 6 variable axes 8個の変数軸を持った脂質と糖質のレーダーチャート  Lipid and carbohydrate radar chart with 8 variable axes 6個の変数軸を持った脂質の質のレーダーチャート  Lipid quality radar chart with 6 variable axes

符号の説明Explanation of symbols

(1)肥満度
(2)総コレステロール値
(3)LDLコレステロール値
(4)HDLコレステロール値
(5)中性脂肪値
(6)乳ビ値
(7)小粒子LDL
(8)ミッドバンド(IDL)
(9)正常基準輪
(10)正常人では出現しない部分
(11)健診患者Aの結果
(12)総コレステロール値
(13)LDLコレステロール値
(14)HDLコレステロール値
(15)中性脂肪値
(16)小粒子LDL
(17)ミッドバンド
(18)正常基準輪
(19)健診患者Bの結果
(20)総コレステロール値
(21)LDLコレステロール値
(22)HDLコレステロール値
(23)中性脂肪値
(24)血糖値
(25)ヘモグロビンA1C
(26)小粒子LDL
(27)ミッドバンド(IDL)
(28)正常基準輪
(29)健診患者Cの結果
(30)VLDL
(31)IDL
(32)LDL
(33)Small LDL
(34)HDL
(35)乳ビ
(36)正常基準輪
(37)患者の検査結果が存在しない部分
(37)健診患者Dの結果
(1) Obesity level (2) Total cholesterol level (3) LDL cholesterol level (4) HDL cholesterol level (5) Triglyceride level (6) Milky level (7) Small particle LDL
(8) Midband (IDL)
(9) Normal reference wheel (10) Portion not appearing in normal person (11) Results of medical examination patient A (12) Total cholesterol level (13) LDL cholesterol level (14) HDL cholesterol level (15) Triglyceride level ( 16) Small particle LDL
(17) Midband (18) Normal reference wheel (19) Results of medical examination patient B (20) Total cholesterol level (21) LDL cholesterol level (22) HDL cholesterol level (23) Triglyceride level (24) Blood glucose level (25) Hemoglobin A1C
(26) Small particle LDL
(27) Midband (IDL)
(28) Normal reference wheel (29) Results of medical examination patient C (30) VLDL
(31) IDL
(32) LDL
(33) Small LDL
(34) HDL
(35) Milk pin (36) Normal reference wheel (37) Part where patient test result does not exist (37) Result of medical examination patient D

Claims (6)

脂質の質と量を1つのレーダーチャートで表記しひと目で脂質全体の状況がわかるようにした事を特長とする脂質の質と量の全体像を把握する方法A method for grasping the overall picture of the quality and quantity of lipids, which features the quality and quantity of lipids on a single radar chart so that the status of the whole lipid can be understood at a glance. 脂質の質の検査結果として、リポ蛋白電気泳動法の分析結果であるVLDLやミッドバンド、LDL、小粒子LDL、HDLの内少なくとも2種類以上をレーダーチャートに取り入れたことを特長とする請求項1の脂質の質と量の全体像を把握する方法2. The radar chart includes at least two types of VLDL, midband, LDL, small particle LDL, and HDL, which are analysis results of lipoprotein electrophoresis, as lipid quality test results. To understand the overall picture of lipid quality and quantity 脂質または糖質の量の検査結果として、総コレステロール、LDLコレステロール、HDLコレステロール、中性脂肪、血糖値、ヘモグロビンA1Cの測定値の内少なくとも2種類以上をレーダーチャートに取り入れたことを特長とする請求項1の脂質の質と量の全体像を把握する方法Claims characterized in that at least two or more of total cholesterol, LDL cholesterol, HDL cholesterol, neutral fat, blood sugar level, and hemoglobin A1C measurement values are incorporated into the radar chart as a test result of the amount of lipid or carbohydrate. Method of grasping the whole picture of the quality and quantity of lipid of Item 1 脂質代謝の1つの表現である肥満度をレーダーチャートに取り入れたことを特長とする請求項1の脂質の質と量の全体像を把握する方法The method for grasping the overall picture of the quality and quantity of lipid according to claim 1, wherein obesity level, which is one expression of lipid metabolism, is incorporated in a radar chart. 血液の脂質による濁り度である乳ビ量を目視判定またはホルマジン濃度で表しそれをレーダーチャートに取り入れたことを特長とする請求項1の脂質の質と量の全体像を把握する方法The method of grasping the whole picture of the quality and quantity of lipid according to claim 1, wherein the amount of milk milk, which is turbidity due to lipids in blood, is visually determined or expressed by a formazine concentration and incorporated in a radar chart. 脂質の質として、酸化LDLの量または酸化HDLの量をレーダーチャートに取り入れたことを特長とする請求項1の脂質の質と量の全体像を把握する方法The method for grasping the overall picture of the quality and amount of lipid according to claim 1, wherein the amount of oxidized LDL or the amount of oxidized HDL is taken into the radar chart as the quality of lipid.
JP2004247545A 2004-08-02 2004-08-02 Method for grasping whole picture in quality and quantity of fat Pending JP2006043360A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004247545A JP2006043360A (en) 2004-08-02 2004-08-02 Method for grasping whole picture in quality and quantity of fat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004247545A JP2006043360A (en) 2004-08-02 2004-08-02 Method for grasping whole picture in quality and quantity of fat

Publications (1)

Publication Number Publication Date
JP2006043360A true JP2006043360A (en) 2006-02-16

Family

ID=36022550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004247545A Pending JP2006043360A (en) 2004-08-02 2004-08-02 Method for grasping whole picture in quality and quantity of fat

Country Status (1)

Country Link
JP (1) JP2006043360A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009022671A (en) * 2007-07-23 2009-02-05 Fukuda Denshi Co Ltd Device and method for biological information processing
WO2010062535A1 (en) * 2008-10-27 2010-06-03 Medtronic Minimed, Inc. Methods and systems for evaluating glycemic control
JP2021500172A (en) * 2017-10-26 2021-01-07 アムラ・メディカル・エービーAMRA Medical AB Evaluation of individual characteristics of at least one phenotypic variable

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009022671A (en) * 2007-07-23 2009-02-05 Fukuda Denshi Co Ltd Device and method for biological information processing
WO2010062535A1 (en) * 2008-10-27 2010-06-03 Medtronic Minimed, Inc. Methods and systems for evaluating glycemic control
JP2021500172A (en) * 2017-10-26 2021-01-07 アムラ・メディカル・エービーAMRA Medical AB Evaluation of individual characteristics of at least one phenotypic variable
JP7413257B2 (en) 2017-10-26 2024-01-15 アムラ・メディカル・エービー Assessment of individual characteristics of at least one phenotypic variable

Similar Documents

Publication Publication Date Title
Demmer et al. The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP)
Bruce et al. Predictors of cognitive impairment and dementia in older people with diabetes
Ol Canadian Study of Health and Aging: study methods and prevalence of dementia
Barzilay et al. Albuminuria and dementia in the elderly: a community study
Hillier et al. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis: The DESIR Cohort
Rigaud et al. Patients with Alzheimer's disease living at home in France: costs and consequences of the disease
Mantha et al. Usefulness of routine preoperative testing: a prospective single-observer study
Al-Maskari et al. The prevalence of macrovascular complications among diabetic patients in the United Arab Emirates
Rönnemaa et al. Glucose metabolism and the risk of Alzheimer’s disease and dementia: a population-based 12 year follow-up study in 71-year-old men
Ladha et al. Role of patient‐centred outcomes after hospital discharge: a state‐of‐the‐art review
Saarikko et al. Continuous 7-month internet of things–based monitoring of health parameters of pregnant and postpartum women: Prospective observational feasibility study
Jelinek et al. An innovative multi-disciplinary diabetes complications screening program in a rural community: A description and preliminary results of the screening
Christophi et al. Confirming glycemic status in the diabetes prevention program: implications for diagnosing diabetes in high risk adults
Annweiler et al. Association between serum 25-hydroxyvitamin D concentration and optic chiasm volume.
El-Shazly et al. Health care for diabetic patients in developing countries: a case from Egypt
Bruce et al. Vascular depression in older people with diabetes
Hertiš et al. The prevalence of elevated blood pressure in a sample of Slovene children and adolescents: a pilot study
Karras et al. Utility of routine testing for patients with asymptomatic severe blood pressure elevation in the emergency department
Wilson et al. Use of the brief Confusion Assessment Method in a veteran palliative care population: A pilot validation study
Lowe et al. Hyperglycemia and adverse pregnancy outcome (HAPO) study: an overview
Sanchez-Carrillo Bias due to conjunctiva hue and the clinical assessment of anemia
JP2006043360A (en) Method for grasping whole picture in quality and quantity of fat
Mayurasakorn et al. Glycemic control and microvascular complications among type 2 diabetes at primary care units
Tilvis et al. Urinary incontinence as a predictor of death and institutionalization in a general aged population
Zaal-Schuller et al. The prevalence of peripheral arterial disease in middle-aged people with intellectual disabilities

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080311